7月6日，康方生物盘中上涨3.32%，报104.4港元，成交额2.11亿港元。
消息面上，国家医保局近期公布医保目录初审结果，共557个药品通过医保目录初审、54个药品通过商保创新药目录初审，"医保+商保"双目录谈判进入实质推进阶段，叠加预申报机制、8年价格保护等新机制同步落地，为创新药商业化提供稳定政策预期。康方生物5款自研新药全部适应症已纳入国家医保，新药奇佑康完成全国首批发货，有望加速市场放量。同板块荣昌生物涨3.82%、科伦博泰生物涨3.11%、三生制药涨2.92%，行业beta共振延续。此外，多家券商近期维持公司"买入"评级，中信建投预计公司营收将保持高速增长，核心产品依沃西全球市场空间广阔。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.